Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions [0.03%]
胰腺导管腺癌的新兴治疗策略：进展与未来方向
Chengwei Peng,Paul E Oberstein
Chengwei Peng
Pancreatic adenocarcinoma remains a leading cause of cancer-related mortality worldwide. Although surgery can be curable for a subset of patients, the five-year overall survival remains less than 15%. Despite extensive molecular characteriz...
Management of Advanced Stage Endometrial Cancer With Non-Measurable Disease After Surgery [0.03%]
术后晚期子宫内膜癌非测量型疾病患者的治疗方案
Stephanie M Wang,Julia Dexter,Rebecca Wolsky et al.
Stephanie M Wang et al.
Patients with advanced stage completely resected endometrial cancer represent a heterogeneous group and decision-making regarding adjuvant treatment for this patient population is complex. When considering this cohort of patients, factors s...
Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML [0.03%]
适合和不适合强化治疗的初治急性髓系白血病患者的治疗选择的新进展
Gray H Magee,Michael R Grunwald
Gray H Magee
The integration of next-generation sequencing (NGS) and advanced cytogenetic diagnostics into routine clinical practice is reshaping frontline treatment of acute myeloid leukemia (AML) in both fit and unfit patients. Molecular profiling now...
Revolutionizing Breast Cancer Therapeutics: Intersecting Frontiers of Precision Medicine, Nanotechnology, and Drug Delivery Innovations [0.03%]
精准医疗、纳米技术和药物输送创新在乳腺癌治疗中的交叉前沿研究与发展革新
Anandini Chattopadhyay,Falak Goyal,Abhishek Sehrawat et al.
Anandini Chattopadhyay et al.
The ongoing challenge of addressing breast cancer, one of the most prevalent cancers and a principal cause of mortality among women globally, has reached a critical juncture with the advent of precision medicine and the promise of nanotechn...
Navigating PARP Inhibitor Resistance in Ovarian Cancer: Bridging Mechanistic Insights To Clinical Translation [0.03%]
卵巢癌PARP抑制剂耐药的应对策略：从机制洞见至临床转化
Ziyi Wang,Yuting Liu,Qing Yang
Ziyi Wang
PARP inhibitors (PARPi) are increasingly vital in treating, particularly in individuals exhibiting homologous recombination deficiency (HRD), harnessing synthetic lethality to target tumor cells. However, PARPi resistance severely restricts...
Skin Reactions and Other Underappreciated Dermatologic Side Effects of Cancer Therapies [0.03%]
被忽视的癌症治疗皮肤反应及其他皮肤病学副作用
Hue T T Tran,Thuy M Tran,Duc V Le et al.
Hue T T Tran et al.
Cutaneous adverse events (cAEs) are among the most common toxicities associated with modern cancer therapies, which are particularly heightened among immunotherapies and targeted agents. Despite being frequently immune-mediated, the majorit...
Dyadic Interventions for LGBTQ+ Individuals Facing Cancer: A Narrative Review [0.03%]
面向癌症患者的LGBTQ+人群的双边干预措施：叙述性综述
Milena E Insalaco,Viktor Clark,Jeffrey Ramos-Santiago et al.
Milena E Insalaco et al.
Dyadic interventions are uniquely positioned not only to improve psychosocial outcomes for those with cancer, but also to improve caregiver and relationship outcomes. Although dyadic interventions have demonstrated efficacy in reducing dist...
Re-thinking the Role of Thoracic Radiotherapy in the First-Line Treatment for Extensive-Stage Small Cell Lung Cancer [0.03%]
重新思考胸部放射治疗在广泛期小细胞肺癌一线治疗中的作用
Guo Lin,Fan Ge,Chao Yang et al.
Guo Lin et al.
Extensive-stage small cell lung cancer (ES-SCLC) remains a challenging disease with a poor prognosis, despite recent advances in immunotherapy. The integration of thoracic radiotherapy (TRT) with chemoimmunotherapy has emerged as a promisin...
Covalent and Non-Covalent BTK Inhibition in Chronic Lymphocytic Leukemia Treatment [0.03%]
慢性淋巴细胞白血病治疗中的共价和非共价BTK抑制剂疗法
Pratik V Shah,Douglas E Gladstone
Pratik V Shah
Bruton's tyrosine kinase (BTK) inhibitors are transforming chronic lymphocytic leukemia (CLL) treatment. Given the availability of both covalent and non-covalent BTK inhibitors (BTKis) CLL treatment has become more nuanced. Here the mechani...
A Milestone in the Shift from "Passive Killing" to "Active Immunomodulation" in Cancer Treatment-Progress in Melanoma Vaccine Research [0.03%]
从“被动杀伤”到“主动免疫调节”的癌症治疗转型中的一个里程碑——黑色素瘤疫苗研究的进展
Yuke Zhang,Jie Liu,Xiyue Chang et al.
Yuke Zhang et al.
Melanoma is the most malignant skin tumor and exhibits extremely aggressive behavior with a high tendency to metastasize. Although the 5-year survival rate of early-stage patients (stage I-II) can reach over 90%, intermediate- and late-stag...